Completed PHASE2 INTERVENTIONAL 1-arm NCT04188847

First-line Chemotherapy for Recurrent Cervical Cancer

Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial

Sponsor: Lei Li

Conditions Apatinib Chemotherapy Persistent Advanced Cervical Carcinoma Recurrent Cervical Carcinoma Targeted Therapy Vascular Endothelial Growth Factor 2 Inhibitor

Interventions Chemotherapy plus apatinib

Updated 6 times since 2020 Last updated: Mar 12, 2022 Started: Dec 6, 2019 Primary completion: Feb 6, 2022 Completion: Mar 13, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Apatinib and Chemotherapy, this trial is completed. The trial is conducted by Lei Li and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2022 — Apr 2022 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Jan 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China